Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Tarsus Pharmaceuticals Inc's Business Segments
Tarsus Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 162
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 162 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product89.7%
- License and Collaboration10.3%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 145 | 89.7% |
| License and Collaboration | $ 17 | 10.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing innovative therapeutics for various ophthalmic conditions. The company was founded in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals focuses on the discovery and development of novel treatments to address unmet needs in ophthalmology. They aim to improve patient outcomes and enhance the overall quality of care in this field. The company primarily focuses on developing medications that target diseases of the eyelids, tear film, and ocular surface.
One of the core areas of research and development at Tarsus Pharmaceuticals is their work on meibomian gland dysfunction (MGD), a chronic condition that affects the function of the meibomian glands in the eyelids, leading to various ocular symptoms. They have developed a proprietary therapeutic called TP-03, which is designed to target the underlying causes of MGD and provide long-lasting relief to patients.
TP-03 is a broad-spectrum antibiotic that inhibits the growth of bacteria that contribute to MGD. It also has anti-inflammatory properties and helps to restore the natural lipid layer of the tear film. Tarsus Pharmaceuticals has conducted clinical trials on TP-03, demonstrating its safety and efficacy in addressing the signs and symptoms of MGD.
In addition to their work on MGD, Tarsus Pharmaceuticals is also actively engaged in developing treatments for other conditions, including dry eye disease, blepharitis, and ocular rosacea. Their research encompasses both small molecule therapeutics and biologics.
The company has a strong focus on collaboration and partnerships. They have established relationships with various academic institutions, research organizations, and industry leaders to accelerate the development of their pipeline and bring innovative treatments to market.
Tarsus Pharmaceuticals is committed to adhering to the highest scientific and ethical standards in their research and development processes. They conduct rigorous clinical trials to ensure that their therapeutics are safe, effective, and meet regulatory requirements.
Overall, Tarsus Pharmaceuticals Inc is a cutting-edge biopharmaceutical company that is dedicated to revolutionizing the treatment landscape for ophthalmic conditions. Through their innovative research, development, and partnerships, they aim to make a significant impact on patient care and improve the quality of life for individuals suffering from various eye disorders.
Tarsus Pharmaceuticals focuses on the discovery and development of novel treatments to address unmet needs in ophthalmology. They aim to improve patient outcomes and enhance the overall quality of care in this field. The company primarily focuses on developing medications that target diseases of the eyelids, tear film, and ocular surface.
One of the core areas of research and development at Tarsus Pharmaceuticals is their work on meibomian gland dysfunction (MGD), a chronic condition that affects the function of the meibomian glands in the eyelids, leading to various ocular symptoms. They have developed a proprietary therapeutic called TP-03, which is designed to target the underlying causes of MGD and provide long-lasting relief to patients.
TP-03 is a broad-spectrum antibiotic that inhibits the growth of bacteria that contribute to MGD. It also has anti-inflammatory properties and helps to restore the natural lipid layer of the tear film. Tarsus Pharmaceuticals has conducted clinical trials on TP-03, demonstrating its safety and efficacy in addressing the signs and symptoms of MGD.
In addition to their work on MGD, Tarsus Pharmaceuticals is also actively engaged in developing treatments for other conditions, including dry eye disease, blepharitis, and ocular rosacea. Their research encompasses both small molecule therapeutics and biologics.
The company has a strong focus on collaboration and partnerships. They have established relationships with various academic institutions, research organizations, and industry leaders to accelerate the development of their pipeline and bring innovative treatments to market.
Tarsus Pharmaceuticals is committed to adhering to the highest scientific and ethical standards in their research and development processes. They conduct rigorous clinical trials to ensure that their therapeutics are safe, effective, and meet regulatory requirements.
Overall, Tarsus Pharmaceuticals Inc is a cutting-edge biopharmaceutical company that is dedicated to revolutionizing the treatment landscape for ophthalmic conditions. Through their innovative research, development, and partnerships, they aim to make a significant impact on patient care and improve the quality of life for individuals suffering from various eye disorders.
Tarsus Pharmaceuticals Inc. is a notable player in the field of ophthalmology, dedicated to developing and commercializing innovative therapies aimed at a wide range of eye disorders. The company structures its initiatives around several key segments, products, and services, which collectively embody its commitment to addressing unmet medical needs in this domain.
1. Segments
a. Preservative-Free Therapeutics
Tarsus Pharmaceuticals champions the advancement of preservative-free therapies. These therapies are designed to mitigate the adverse effects often associated with conventional eye drops that contain preservatives, which can lead to ocular discomfort and complications over time. Tarsus recognizes the necessity for gentler alternatives that can provide more effective relief without the risk of irritation or toxicity to the eyes.
b. Anterior and Posterior Eye Disorders
The company prioritizes solutions applicable to both anterior (front of the eye) and posterior (back of the eye) segments. This dual-focus allows Tarsus to address a comprehensive range of ocular conditions, from more common afflictions such as dry eye and allergies to complex diseases that could potentially lead to severe vision impairment or blindness if left untreated.
Products
a. TP-03
The hallmark product candidate of Tarsus Pharmaceuticals is TP-03, an innovative therapeutic specifically formulated to treat Demodex blepharitis. This condition is caused by an infestation of Demodex mites on the eyelids, which can lead to symptoms like irritation, redness, and inflammation. TP-03’s formulation is distinct in its approach to target and eliminate these mites, effectively addressing the root cause. It showcases the company’s commitment to developing cutting-edge solutions that can both improve patient outcomes and enhance quality of life.
b. Proprietary Drug Delivery Technology
An important aspect of Tarsus’s product line is its proprietary drug delivery technology, which enhances the targeting and bioavailability of its therapeutic agents. This technology is designed to optimize how drugs are delivered to the ocular surface, improving their efficacy and minimizing systemic exposure. Such advancements ensure that patients receive the maximum benefits from their medications while limiting potential side effects.
c. Pipeline Products
Tarsus boasts a diverse pipeline of therapeutic candidates at various stages of development, targeting a multitude of eye disorders. These include, but are not limited to, conditions such as dry eye disease, meibomian gland dysfunction, and ocular allergies. Each of these pipeline products is intended to fill existing gaps in treatment modalities available to healthcare practitioners, thereby expanding the therapeutic options for patients suffering from these conditions.
Services
a. Clinical Trials
To substantiate the safety and efficacy of its investigational drugs, Tarsus Pharmaceuticals conducts rigorous clinical trials. These trials are vital for gathering comprehensive data on each product candidate, involving meticulous testing and oversight to evaluate therapeutic benefits and identify potential side effects. Tarsus is committed to conducting ethical and scientifically sound trials to ensure reliable outcomes that can inform future clinical use.
b. Regulatory Affairs
Tarsus also offers a suite of regulatory affairs services aimed at ensuring compliance with both local and international regulations throughout the lifecycle of its products. This encompasses obtaining essential approvals, managing documentation, and navigating complex regulatory landscapes to meet the necessary standards for product commercialization. By proactively engaging in regulatory affairs, Tarsus positions itself to swiftly bring its innovations to market.
Strategic Partnerships
In its quest to accelerate the development and commercialization of its products, Tarsus Pharmaceuticals actively seeks collaborations with academic institutions, research organizations, and other industry partners. These strategic partnerships facilitate the exchange of resources, knowledge, and expertise, ultimately enhancing the company’s research capabilities and speed to market. Such collaborations are pivotal in driving innovation and ensuring that Tarsus remains at the forefront of ophthalmic therapeutics.
Conclusion
In summary, Tarsus Pharmaceuticals Inc. is dedicated to pioneering innovative, preservative-free therapies for a variety of eye disorders. Its flagship product, TP-03, represents a significant advancement for patients suffering from Demodex blepharitis. With a robust pipeline of potential therapies, proprietary drug delivery technology, and a commitment to rigorous clinical research and regulatory compliance, Tarsus Pharmaceuticals continues to make strides in the ophthalmology sector. Strategic partnerships further enhance its capacity to deliver novel treatments that address the evolving needs of patients and healthcare providers alike.
1. Segments
a. Preservative-Free Therapeutics
Tarsus Pharmaceuticals champions the advancement of preservative-free therapies. These therapies are designed to mitigate the adverse effects often associated with conventional eye drops that contain preservatives, which can lead to ocular discomfort and complications over time. Tarsus recognizes the necessity for gentler alternatives that can provide more effective relief without the risk of irritation or toxicity to the eyes.
b. Anterior and Posterior Eye Disorders
The company prioritizes solutions applicable to both anterior (front of the eye) and posterior (back of the eye) segments. This dual-focus allows Tarsus to address a comprehensive range of ocular conditions, from more common afflictions such as dry eye and allergies to complex diseases that could potentially lead to severe vision impairment or blindness if left untreated.
Products
a. TP-03
The hallmark product candidate of Tarsus Pharmaceuticals is TP-03, an innovative therapeutic specifically formulated to treat Demodex blepharitis. This condition is caused by an infestation of Demodex mites on the eyelids, which can lead to symptoms like irritation, redness, and inflammation. TP-03’s formulation is distinct in its approach to target and eliminate these mites, effectively addressing the root cause. It showcases the company’s commitment to developing cutting-edge solutions that can both improve patient outcomes and enhance quality of life.
b. Proprietary Drug Delivery Technology
An important aspect of Tarsus’s product line is its proprietary drug delivery technology, which enhances the targeting and bioavailability of its therapeutic agents. This technology is designed to optimize how drugs are delivered to the ocular surface, improving their efficacy and minimizing systemic exposure. Such advancements ensure that patients receive the maximum benefits from their medications while limiting potential side effects.
c. Pipeline Products
Tarsus boasts a diverse pipeline of therapeutic candidates at various stages of development, targeting a multitude of eye disorders. These include, but are not limited to, conditions such as dry eye disease, meibomian gland dysfunction, and ocular allergies. Each of these pipeline products is intended to fill existing gaps in treatment modalities available to healthcare practitioners, thereby expanding the therapeutic options for patients suffering from these conditions.
Services
a. Clinical Trials
To substantiate the safety and efficacy of its investigational drugs, Tarsus Pharmaceuticals conducts rigorous clinical trials. These trials are vital for gathering comprehensive data on each product candidate, involving meticulous testing and oversight to evaluate therapeutic benefits and identify potential side effects. Tarsus is committed to conducting ethical and scientifically sound trials to ensure reliable outcomes that can inform future clinical use.
b. Regulatory Affairs
Tarsus also offers a suite of regulatory affairs services aimed at ensuring compliance with both local and international regulations throughout the lifecycle of its products. This encompasses obtaining essential approvals, managing documentation, and navigating complex regulatory landscapes to meet the necessary standards for product commercialization. By proactively engaging in regulatory affairs, Tarsus positions itself to swiftly bring its innovations to market.
Strategic Partnerships
In its quest to accelerate the development and commercialization of its products, Tarsus Pharmaceuticals actively seeks collaborations with academic institutions, research organizations, and other industry partners. These strategic partnerships facilitate the exchange of resources, knowledge, and expertise, ultimately enhancing the company’s research capabilities and speed to market. Such collaborations are pivotal in driving innovation and ensuring that Tarsus remains at the forefront of ophthalmic therapeutics.
Conclusion
In summary, Tarsus Pharmaceuticals Inc. is dedicated to pioneering innovative, preservative-free therapies for a variety of eye disorders. Its flagship product, TP-03, represents a significant advancement for patients suffering from Demodex blepharitis. With a robust pipeline of potential therapies, proprietary drug delivery technology, and a commitment to rigorous clinical research and regulatory compliance, Tarsus Pharmaceuticals continues to make strides in the ophthalmology sector. Strategic partnerships further enhance its capacity to deliver novel treatments that address the evolving needs of patients and healthcare providers alike.